Bionoxx Inc. (Bionoxx), founded in 2016, is committed to demystifying the functional heterogeneity of circulating neutrophils in cancer as well as immune-related diseases. Based on BNX-IFS (Immune Function States), a unique assay that detects activated neutrophils implicated in impaired immune homeostasis, we have shown effective immunomodulatory strategies in the treatment of ICI-resistant tumor mice model and viral sepsis mice model. Employing this strategy, Bionoxx obtained USFDA acceptance to proceed with a first-in-human trial with Immuno-Oncology (IO) virotherapy (mOTS-400) aimed at overcoming ICI resistance. BNX-IFS's ability to detect specific immune states in circulating blood is essential for tailoring immunomodulatory strategies across immune-related conditions. BNX is actively seeking partnerships with leading pharmaceutical companies to further our mission and make significant strides in the field of immunotherapy.